The Genitourinary Drugs Market is set to reach USD 28,200 million and expected to register CAGR ~1.65% by 2023; according to a new research report by Market Research Future. Global Genitourinary Drugs Market: Information by Disease (Urinary Tract Infections, Erectile Dysfunction, Hematuria, and Others), Product (Urological, Hormonal Therapy, and Others), End-User (Hospitals, Super specialty clinics) — Global Forecast till 2023
Genitourinary Drugs Market – Overview
Genitourinary Disorders are caused by damage to urinal or genital part of the human body. Kidney, bladder, ureter and urethra are parts of genitourinary system, genitourinary drugs are used to treat the medical complications caused to these parts. The rising prevalence of genitourinary disorders, increasing number of pipeline drugs, and technological advancement in genitourinary diagnosis are expected to drive the growth of the market. According to the U.S. National Library of Medicine more than 480 clinical trials are lined up for treatment of urinary tract infection.
The increasing appearance of drug counterfeiting in pharmaceutical industry, intense competition from generic manufacturers and drug patent expirations are likely to hinder market growth during the forecast period.
Get Free Sample @ https://www.marketresearchfuture.com/sample_request/6802
Genitourinary Drugs Market – Key Players
Some of the key players in the Global Genitourinary Drugs Market are
- Bayer AG
- Astellas Pharma Inc.
- Pfizer Inc.
- Eli Lilly and Company
- Genentech, Inc.
- Immunex Corp
- GlaxoSmithKline plc.
- Ionis Pharmaceuticals, Inc.
- Merck & Co.
- Bristol-Myers Squibb Company
- Antares Pharma
- Novartis AG
Genitourinary Drugs Market – Segmentation
The Global Genitourinary Drugs Market has been segmented on the basis of disease, product, and end user.
The market, by disease, has been classified as urinary tract infections, erectile dysfunction, urinary incontinence and overactive bladder, kidney/renal cancer, genitourinary cancer, bladder cancer, bladder cancer, cervical cancer, sexually transmitted diseases, interstitial cystitis, hematuria, ovarian cancer, and prostate cancer.
On the basis of product, the market has been segregated into urological, hormonal therapy, gynecological, and anti-infectives.
The end user segment has been divided into, hospitals, clinics, super specialty centers, and others.
Genitourinary Drugs Market – Regional Analysis
The market in the Americas is expected to dominate the Global Genitourinary Drugs Market during the forecast period owing to the rising prevalence of genitourinary disorders, increasing number of cancer patients in the region, the rise in healthcare expenditure, and the presence of a well-established healthcare system. The European market is expected to be the second-largest due to government initiatives for the development of the healthcare sector, increasing research and development activities in the region, and the rise in a number of chronic disorders. Moreover, the market in Asia-Pacific is anticipated to be the fastest-growing market during the forecast period owing to the increasing geriatric population, rising investments in the healthcare sector, and favorable government policies. The market in the Middle East and Africa is likely to account for the smallest share of the global genitourinary drugs market. The market growth in this region can be attributed to increasing healthcare expenditure and growing medical tourism.
About Market Research Future:
At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.
In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Market Research Future
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar
Pune – 411028
+1 646 845 9312